ストックスクリーナーアプリを入手
108.28
0.06%
0.06
アフターアワーズ：
108.31
0.03
+0.03%
前日終値:
$108.22
開ける：
$108.38
24時間の取引高:
3.57M
Relative Volume:
0.44
時価総額：
$134.69B
収益：
$28.73B
当期純損益:
$5.97B
株価収益率:
22.80
EPS:
4.75
ネットキャッシュフロー:
$9.84B
1週間 パフォーマンス:
-3.40%
1か月 パフォーマンス:
-0.20%
6か月 パフォーマンス:
+16.48%
1年 パフォーマンス:
+49.23%
1日の値動き範囲:
$107.75
$109.38
1週間の範囲:
$107.75
$111.49
52週間の値動き範囲:
$70.78
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
GILD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
108.28 | 139.43B | 28.73B | 5.97B | 9.84B | 4.75 |
|
LLY
Lilly Eli Co
|
762.18 | 717.60B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.36 | 377.32B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
184.85 | 338.30B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.14 | 234.32B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
64.92 | 306.33B | 43.59B | 15.04B | 10.74B | 3.3766 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
After Gilead Deal, Hookipa Hangs Up Its Hat - insights.citeline.com
Gilead Sciences Inc. Stock Analysis and ForecastMarket-leading growth rates - jammulinksnews.com
What drives Gilead Sciences Inc. stock priceExtraordinary market timing - Autocar Professional
Gilead’s HIV Strength Drives Gains, But Pipeline Is Key - Finimize
Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector - MSN
Is Gilead Sciences Inc. a good long term investmentFree Wealth Planning Blueprint - Jammu Links News
Lobbying Update: $90,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Quiver Quantitative
What analysts say about Gilead Sciences Inc. stockRapid wealth multiplication - jammulinksnews.com
HOOKIPA Pharma Inc. Announces Intent to Voluntarily Delist from Nasdaq and Pursue Asset Sale with Gilead Sciences - Quiver Quantitative
HOOKIPA Pharma Exits Nasdaq Market as Gilead Sciences Acquires Key Drug Programs - Stock Titan
Foster City drugs giant Gilead to pay $202 million over alleged kickback scheme - SiliconValley.com
Pennsylvania to receive $1.2M from Gilead over kickback scheme to promote HIV drugs - WPXI
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire
Attorney General Ellison helps secure $200M from Gilead for paying illegal kickbacks - Red Lake Nation News
Gilead Sciences Inc. Agrees to $202 Million Settlement Over Kickbacks, Illinois Leads Charge with Multi-State Coalition - Hoodline
Gilead To Pay $202 Million In Nationwide Settlement Over Illegal HIV Drug Kickback Scheme - MyChesCo
Gilead Sciences CFO Dickinson sells $277k in stock By Investing.com - Investing.com South Africa
Gilead reaches $202M settlement over kickback scheme to promote HIV drug - Crain's New York Business
Troy Griffin on Gilead’s mission at Chosen Few picnic - rollingout.com
Why Merck Is A Better Dividend Stock Than Gilead Sciences (NYSE:MRK) - Seeking Alpha
Nevada to receive over $440K from Gilead settlement over alleged illegal kickbacks - KTVN
Gilead Sciences Advances in Triple-Negative Breast Cancer Treatment - TipRanks
Minnesota and Iowa join $202M Gilead settlement over kickbacks - KIMT
New York AG Letitia James Clinches Monumental $202M Victory Against Gilead Sciences Over HIV Med Kickbacks - Hoodline
Attorney General Raoul Announces More Than $200 Million Settlement With Gilead Sciences Over Illegal Kickbacks To Providers For Prescriptions - RiverBender.com
Pennsylvania to Receive Over $1.2 Million in HIV Drug Kickback Settlement with Gilead - Franklin County Free Press
AG Sunday Part of National Coalition Securing $200M+ from Gilead Sciences for Illegal Kickback Scheme to Sell HIV Drugs - exploreJefferson
GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm - WV News
Gilead’s Vítor Papão on key partnerships and the role of tech in public health - Gulf Business
Attorney General Bonta Helps Secure Over $200 Million from Gilead Sciences for Paying Illegal KickbacksState of California - State of California - Department of Justice (.gov)
Here's Why Gilead Sciences (GILD) Fell More Than Broader Market - Yahoo Finance
Tamar Braxton partners with Gilead for HIV awareness - Rolling Out
Sector Update: Health Care - MarketScreener
Pennsylvania to receive $1.28 million in settlement over Gilead’s illegal HIV drug kickback scheme - WTAJ
Tamar Braxton & Gilead Partner For PrEP Promo To Black Women - Black America Web
Gilead Sciences Reaches $202 Million Settlement Over Kickback Scheme Promoting HIV Drugs - MarketScreener
Pennsylvania Part of National Coalition Securing $200M+ from Gilead Sciences for Illegal Kickback Scheme to Sell HIV Drugs - pennwatch.org
Pennsylvania expected to get $1.28 million from biopharma company for violating anti-kickback laws - ABC27
Massachusetts Secures $1.6 Million from Gilead in $202 Million Multi-State Settlement Over HIV Drug Kickbacks - Hoodline
Gilead reaches $202M settlement over HIV drug speaker program - Seeking Alpha
Tamar Braxton Partners with Gilead to Empower Black Women on HIV Prevention - ThisisRnB.com
Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock - Insider Monkey
Gilead Beats Defamation Suit by Worker Accused of Sex Harassment - Bloomberg Law News
Fighting Disease Requires More Than Just the Right Drug: Gilead - Mexico Business News
Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations - MSN
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25 - BioSpace
Attorney General Schwalb Recovers Over $300,000 from Gilead Sciences for Illegal Kickback Scheme - District of Columbia | Attorney General (.gov)
How the Inhaled Antibiotics Market Will Evolve by 2032Growth, - openPR.com
Gilead's twice-yearly HIV PrEP set for wider rollout - pharmaphorum
Gilead’s twice-yearly HIV prevention shot effective across diverse groups By Investing.com - Investing.com Nigeria
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.38%
大文字化:
|
ボリューム (24 時間):